CD274 and neoplasm: Navulizumab, an anti-PD-1 antibody, can bind to PD-1, block the interaction between PD-1 and PD-L1, thereby relieving the metabolic inhibition of T cells, restoring the function of T cells, and enhancing the immune system’s ability to recognize and eliminate tumor cells [484].